The United Kingdom and the United States have announced a important trade agreement that will guarantee zero levies on British pharmaceutical exports going into the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has agreed to raise spending on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that duties on these key products will be held at zero for a period of 36 months.
This development comes after earlier statements to hike duties on patented drug products, with increases floated reaching 100%.
"This deal with the United Kingdom strengthens the global environment for cutting-edge drugs and brings long-overdue equity to U.S.–U.K. pharmaceutical trade," a statement declared.
Commercial Significance
Medicines are one of the UK's biggest goods shipped to the United States, which is by far the largest buyer for leading companies like GSK and AstraZeneca.
Statistics reveal that in the year prior to September, the UK sold drugs totaling billions to the US. This amount accounted for nearly one-fifth of total UK exports in that span.
"This agreement secures employment, increases capital expenditure and facilitates the UK to emerge as a international leader for medical research," the Business and Trade Secretary commented.
Specific British Pledges
The deal entails several key changes from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a target to raise overall health service expenditure on treatments from 0.3% of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The sum drug companies must pay back to the NHS to stay within budget will be restricted at fifteen percent. In the past, repayments were more than 20%.
Recent Tensions
The pact follows a ongoing row between the drug companies and the British authorities over medicine costs and regulatory access.
These tensions were exacerbated by arguments that US patients were paying significantly more for the identical medicines than people in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been paused or scrapped, while substantial funding commitments have been announced toward US facilities.
The Science Minister stated that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had decreased as a share of its resources over the previous ten-year period.
